Review ArticlesProarrhythmic Manifestations of Neuromuscular DystrophinopathiesCatanzaro, John N. MD*; Chan, Nicholas MD, MS†,‡; Ismail, Haisam MD†,‡; Huddleston, Daniel MD§; Makaryus, Amgad N. MD†,‡,¶; Makaryus, John N. MD†,‡,‖Author Information From the *Department of Cardiology, University of Florida Health Science Center, Jacksonville, FL; †Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; ‡Department of Cardiology, North Shore University Hospital/Northwell Health, Manhasset, NY; §Department of Neurology, Emory University, Atlanta, GA; ¶Department of Cardiology, Nassau University Medical Center, East Meadow, NY; and ‖Feinstein Institute for Medical Research at Northwell Health, Manhasset, NY. Disclosure: The authors have no conflicts of interest to report. Correspondence: Nicholas Chan, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Department of Cardiology North Shore University Hospital 300 Community Drive Manhasset, NY 11030. E-mail: [email protected] Cardiology in Review: March/April 2021 - Volume 29 - Issue 2 - p 68-72 doi: 10.1097/CRD.0000000000000305 Buy Metrics Abstract Muscular dystrophy has been an elusive term ever since it was first described in the 19th century. Introduced in 1891 by Wilhelm Heinrich Erb, muscular dystrophy has been classified as part of a larger group of genetically determined, progressive degenerative neuromuscular disorders termed “dystrophinopathies.” Cardiac arrhythmias may occur during the neurologic course of the disease. Although descriptions of the dystrophinopathies have been reported in the literature, few articles address the use of antiarrhythmic pharmacotherapy in patients with muscular dystrophy. We discuss the pathophysiology of the most common dystrophinopathies, their proarrhythmic sequelae, and the therapeutic use of antiarrhythmic agents in the clinical setting. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.